Mifeprex patent extension
Danco Labs expects Mifeprex (mifepristone, RU-486) to receive a two-year patent extension as a result of FDA's reassessment of the regulatory review period for the abortion drug, in lieu of the four-year extension originally expected. FDA said in an Oct. 24 Federal Register notice that it changed its determination of the start date for the Mifeprex IND from 1994 to the pre-Waxman/Hatch date of 1983 (1"The Pink Sheet" Oct. 28, p. 21). A two-year extension will give Mifeprex exclusivity through January 2004...
You may also be interested in...
The patent life of Danco Labs/The Population Council's Mifeprex (mifepristone, RU-486) will be shortened following a determination by FDA that the abortifacient IND became "effective" in 1983 rather than 1994
A recent court case and an upcoming federal election promise movement in Germany's cannbidiol market, stated Joscha Krauss, CEO of local manufacturer MH Medical Hemp GmbH, at the 18th European Industrial Hemp Association (EIHA) Annual Conference.
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.